Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Garijo will be the first woman to lead Sanofi in its history
Subscribe To Our Newsletter & Stay Updated